JP2023501253A5 - - Google Patents

Info

Publication number
JP2023501253A5
JP2023501253A5 JP2022525496A JP2022525496A JP2023501253A5 JP 2023501253 A5 JP2023501253 A5 JP 2023501253A5 JP 2022525496 A JP2022525496 A JP 2022525496A JP 2022525496 A JP2022525496 A JP 2022525496A JP 2023501253 A5 JP2023501253 A5 JP 2023501253A5
Authority
JP
Japan
Prior art keywords
trifluoromethyl
alkyl
piperidine
oxy
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525496A
Other languages
English (en)
Japanese (ja)
Other versions
JP7641957B2 (ja
JP2023501253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057831 external-priority patent/WO2021087025A1/en
Publication of JP2023501253A publication Critical patent/JP2023501253A/ja
Publication of JP2023501253A5 publication Critical patent/JP2023501253A5/ja
Application granted granted Critical
Publication of JP7641957B2 publication Critical patent/JP7641957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525496A 2019-10-30 2020-10-29 Parp7阻害剤としてのピリダジノン Active JP7641957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927934P 2019-10-30 2019-10-30
US62/927,934 2019-10-30
PCT/US2020/057831 WO2021087025A1 (en) 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors

Publications (3)

Publication Number Publication Date
JP2023501253A JP2023501253A (ja) 2023-01-18
JP2023501253A5 true JP2023501253A5 (enExample) 2023-11-02
JP7641957B2 JP7641957B2 (ja) 2025-03-07

Family

ID=73699388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525496A Active JP7641957B2 (ja) 2019-10-30 2020-10-29 Parp7阻害剤としてのピリダジノン

Country Status (13)

Country Link
US (2) US11691969B2 (enExample)
EP (1) EP4051384A1 (enExample)
JP (1) JP7641957B2 (enExample)
KR (1) KR20220109401A (enExample)
CN (1) CN114761086B (enExample)
AR (1) AR120338A1 (enExample)
AU (1) AU2020375821B2 (enExample)
CA (1) CA3159188A1 (enExample)
IL (1) IL292432B1 (enExample)
MX (1) MX2022005216A (enExample)
PH (1) PH12022551013A1 (enExample)
TW (1) TWI902715B (enExample)
WO (1) WO2021087025A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达(四川)生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
EP4291560A4 (en) * 2021-02-09 2025-01-15 Jacobio Pharmaceuticals Co., Ltd. TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CN117279917A (zh) * 2021-05-21 2023-12-22 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (zh) * 2021-08-16 2023-02-23 重庆华森制药股份有限公司 Parp7抑制剂及其应用
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达(四川)生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
EP4570249A4 (en) * 2022-08-09 2026-07-22 Kangbaida Sichuan Biotechnology Co Ltd USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR
TW202416984A (zh) * 2022-08-17 2024-05-01 大陸商北京加科思新藥研發有限公司 化合物i或其鹽的固體形式
CN117164524B (zh) * 2022-09-06 2026-02-03 杭州师范大学 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用
WO2024149231A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN121752568A (zh) * 2023-08-29 2026-03-27 康百达(四川)生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255293B2 (ja) 1997-09-05 2002-02-12 松下電器産業株式会社 蛍光偏光法
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
MX347085B (es) 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
RU2013150102A (ru) 2011-04-11 2015-05-20 Эббви Инк. Ингибиторы parp для лечения cipn
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
JP7382261B2 (ja) 2020-03-19 2023-11-16 株式会社日立製作所 情報処理装置及び方法

Similar Documents

Publication Publication Date Title
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
JP2023529908A5 (enExample)
KR20240050360A (ko) Shp2 단백질 분해활성을 갖는 화합물 및 이들의 의약 용도
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2000128036A (ru) Амидиновые соединения
JP2010538076A5 (enExample)
RU2009140465A (ru) Имидазохинолины с иммуномодулирующими свойствами
JP2007519754A5 (enExample)
MXPA05000081A (es) Quinolinas sustituidas antagonistas del receptor ccr5.
RU2008112221A (ru) Соединения ряда изоиндолимидов, их композиции и способы применения
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2022017221A5 (enExample)
JP2018534282A5 (enExample)
EP1302463A1 (en) Medicine comprising dicyanopyridine derivative
RU2004125146A (ru) Новые соединения
JP2002535323A5 (enExample)
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
CA2529453A1 (en) Pyrrolidin-1,2-dicarboxylic acid-1-[(4-ethinyl-phenyl)-amide]-2-[(phenyl)-amide] derivative as inhibitors of coagulation factors xa and viia for the treatment of thromboses
MXPA05010816A (es) Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer.
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
JP2013536194A5 (enExample)
AU2008240804A1 (en) Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
RU2016108038A (ru) Новые фталазиновые производные и способ их получения
JP2024009891A (ja) T型カルシウムチャネル阻害剤